This is the loosest grouping on the site. GHK-Cu and melanotan II share a broad outcome category and essentially nothing else — not mechanism, not evidence base, not regulatory status, not risk profile. Reading them as alternatives is the mistake this page exists to prevent. Batch certificates are published at /coa.
Stimulation of collagen synthesis in fibroblast cultures by GHK-Cu. PMID 3169264; GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. PMC4508379; EMA: Scenesse (afamelanotide) EPAR; Systemic toxicity and rhabdomyolysis after melanotan II injection. PMID 23121206; Melanoma associated with the use of melanotan-II. PMID 24355990
The route problem comes first
Most search interest in “peptides for skin” is topical — serums, creams, skincare formulations. Body Pharm supplies injectable pens.
For GHK-Cu specifically this is not a detail. It is a defined coordination complex of the GHK tripeptide with copper(II) (what GHK-Cu is), and its behaviour depends on pH, concentration, counter-ions and the rest of the formulation. A cosmetic serum, a clinically studied wound gel and an injectable solution are three genuinely different products. Evidence generated on one does not transfer to the others.
We set that out directly at GHK-Cu injectable vs topical copper peptides.
What the GHK-Cu evidence actually covers
The best-characterised finding is collagen synthesis in fibroblast culture, with stimulation beginning between 10⁻¹² and 10⁻¹¹ M and peaking around 10⁻⁹ M. Reviews describe GHK modulating both synthesis and breakdown of collagen and glycosaminoglycans. GHK occurs naturally in human plasma, at levels reported to fall from around 200 ng/ml at age 20 to roughly 80 ng/ml by 60.
Human work has concerned topical skincare programmes and a specific wound gel. Those results address the formulations they used. They do not establish wrinkle reduction, hair growth, or the benefit and long-term safety of an injectable pen — and we say that on our own product page rather than borrowing the topical literature to support it.
Natural occurrence is also not a safety argument, here or on GHK-Cu’s longevity listing. A molecule present in plasma at nanogram concentrations says nothing about a manufactured, far higher-concentration, differently administered form.
Melanotan II sits in a different category entirely
This is not a cosmetic ingredient with a strong evidence base. It is a non-selective melanocortin agonist (what Melanotan II is): alongside MC1R, which drives pigmentation, it activates MC3R and MC4R, which sit in pathways governing appetite and sexual function. That is the mechanistic reason its reported effects extend well beyond skin.
Its authorised relative, afamelanotide (SCENESSE), is MC1R-selective, EU-authorised since 22 December 2014 under exceptional circumstances for erythropoietic protoporphyria, and supplied as a two-monthly implant placed by a healthcare professional. Melanotan II is not an over-the-counter version of it. Full comparison at Melanotan II vs Melanotan I.
There is no published human dose-ranging trial for melanotan II. The peer-reviewed human record is dominated by case reports, and several describe serious harm — systemic toxicity with rhabdomyolysis, renal injury, changes to existing moles, and melanoma diagnosed in users. It holds no marketing authorisation in the EU or UK, its sale is illegal in the United Kingdom, and the MHRA has warned specifically against unlicensed products marketed for tanning.
The question a skin page should raise and usually doesn’t
Melanocortin signalling stimulates melanocytes — the cell type melanoma arises from. There is no controlled evidence that melanotan II increases melanoma risk, and no controlled evidence that it does not. In a compound whose mechanism directly stimulates that cell line, the absence of long-term safety data is itself the finding.
Anyone considering it should discuss existing moles and skin-cancer risk with a qualified clinician first, and any change to a mole warrants prompt assessment regardless.
Disambiguation
This page covers injectable research compounds. Topical cosmetic peptides are a separate product category under separate regulation, and the two share a word rather than an evidence base. More at cosmetic peptides and what are peptides?.
